| Project/Area Number |
15K20084
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Shiga University of Medical Science |
|---|
Principal Investigator |
Hanada Eiki 滋賀医科大学, 医学部, 助教 (40555067)
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | γグルタミルシクロトランスフェラーゼ / RNA干渉 / 前立腺癌 / γ-グルタミルシクロトランスフェラーゼ / RNAi / GGCT |
|---|
| Outline of Final Research Achievements |
We studied a therapy for prostate cancer by inhibition of GGCT expression. In the immunohisotochemical study using tissue microarray, GGCT was highly expressed in two sections out of 9 sections (22%) of normal human prostate tissue. On the other hand, GGCT was highly expressed in 35 sections out of 40 sections (78%) of prostate cancer tissue. A significant antiproliferative effect via GGCT-targeting siRNA was shown in prostate cancer cell lines, and combination treatment consisting of Docetaxel and GGCT-targeting siRNA reduced cell viability more than the treatment with Docetaxel alone. Therefore, a therapy for prostate cancer by inhibition of GGCT expression may be an effective method.
|
